Olodaterol is a long-acting β₂-agonist (LABA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Developed by Boehringer Ingelheim, it emerged in the early 2000s during efforts to create once-daily bronchodilators with improved lung selectivity and prolonged action. Approved in the 2010s, olodaterol became known for its rapid onset and 24-hour bronchodilation, making it suitable for long-term COPD management. Over time, it has been widely incorporated into fixed-dose combinations with inhaled corticosteroids or long-acting muscarinic antagonists to enhance therapeutic effectiveness and simplify dosing for patients with chronic respiratory disease.
Image
